June 24, 2022
argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe
Breda, the Netherlands
argenx today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended European Commission (EC) approval of efgartigimod as an add-on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.
Past Press Releases
Get photos, fact sheets, illustrations and more.
Join the team
Dare to do more with a thriving career at Argenx.
Get the latest news and info via our social media channels.